Aptevo Therapeutics INC Form 4 insider transactions

Aptevo Therapeutics' EVP and COO, Jeffrey G. Lamothe, reported the conversion of 5 Restricted Stock Units into common stock and the first vesting of a previously granted 17 RSUs, with future vesting scheduled annually.

SoYoung Kwon, SVP, GC, BD & Corp Affairs at Aptevo Therapeutics Inc., reports exercising stock options and Restricted Stock Units (RSUs) converting into common stock.

Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics, reports the vesting of restricted stock units into common stock on March 2nd and 3rd, 2025.

Marvin L. White, President and CEO of Aptevo Therapeutics Inc., reports the acquisition of common stock through the conversion of Restricted Stock Units (RSUs) on March 2nd and 3rd, 2025.

Daphne Taylor, SVP and CFO of Aptevo Therapeutics, reports transactions involving restricted stock units converting into common stock.

SoYoung Kwon, SVP, GC, BD & Corp Affairs of Aptevo Therapeutics Inc., reports the exercise of stock options and subsequent disposal of shares.

Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics, reports the conversion of Restricted Stock Units (RSUs) into common stock.

Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., reports the vesting and conversion of Restricted Stock Units (RSUs) into common stock.

Director Zsolt Harsanyi acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which vest in full on the first anniversary of the grant date.

Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., reports the acquisition of 8,550 Restricted Stock Units (RSUs) that will vest in common stock over three years.

Director Grant Grady III acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which will vest in full on the first anniversary of the grant date.

SVP, GC, BD & Corp Affairs Kwon SoYoung reports acquisition of 8,550 Restricted Stock Units (RSUs) in Aptevo Therapeutics Inc.

Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics Inc., reports acquisition of restricted stock units convertible to common stock.

Aptevo Therapeutics Inc. CEO Marvin L. White acquired 22,325 restricted stock units (RSUs) on July 17, 2024, which will vest in three annual installments starting June 17, 2025.

Director John Niederhuber acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which vest in full on the first anniversary of the grant date.

Director Barbara Lopez Kunz reported the acquisition of Restricted Stock Units (RSUs) in Aptevo Therapeutics Inc. on July 17, 2024.

Director Abdun-Nabi Daniel reports acquisition of 925 Restricted Stock Units (RSUs) in Aptevo Therapeutics, vesting on the first anniversary of the grant date.

Director John Niederhuber reports transactions involving Aptevo Therapeutics' common stock and restricted stock units.

Director Zsolt Harsanyi exercised stock options and converted restricted stock units into common stock of Aptevo Therapeutics on June 1st and 2nd, 2024.

Director Daniel Abdun-Nabi reports exercising restricted stock units for Aptevo Therapeutics common stock.

Director Kunz Barbara Lopez reports acquisition of Aptevo Therapeutics Inc. common stock through vesting of restricted stock units.

Director Grant Grady III reports acquisition of Aptevo Therapeutics common stock through the vesting of restricted stock units.

SVP, GC, BD & Corp Affairs Kwon SoYoung reports the vesting of Restricted Stock Units (RSUs) into common stock of Aptevo Therapeutics Inc.

Daphne Taylor, SVP and CFO of Aptevo Therapeutics, reports the vesting and conversion of restricted stock units into common stock on March 2 and March 4, 2024.

Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics, reports the vesting of restricted stock units and conversion into common stock.

SVP, GC, BD & Corp Affairs Kwon SoYoung reports acquisition of Aptevo Therapeutics Inc. common stock through RSU conversion.

Marvin L. White, President and CEO of Aptevo Therapeutics Inc., converted restricted stock units into common stock on March 2nd and 3rd, 2024.